The near future will offer the same compounds but realized with allogeneic T-cells from healthy donors, tandem CAR T-cells with chimeric receptors for two ligand-binding domains, multi-CAR T-cells for different tumor antigens, complexed built-in-CAR T-cells tie up with anti-PD-L1 moAbs later released into the tumor [72,73,74]. This evidence concerns the gene CD274 and neoplasm.